Development of a dual targeting scaffold of SET7/MLL inhibitor for castration-resistant prostate cancer treatment

Li, Guodong; Hu, Qi; Wong, Vincent Kam Wai; Wang, Wanhe; Leung, Chung‐Hang

doi:10.1016/j.gendis.2023.01.034

Cited by 4 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The well-being of men is facing an escalating threat due to prostate cancer [ 40 , 41 ]. Following radical prostatectomy or chemoradiotherapy, a substantial proportion of patients—ranging from 27% to 53%—have been documented to experience BCR [ 5 ].…”

Section: Discussionmentioning

confidence: 99%

Identification of cell differentiation trajectory-related gene signature to reveal the prognostic significance and immune landscape in prostate cancer based on multiomics analysis

Sun,

Tuo,

Chen

et al. 2024

Heliyon

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Identification of cell differentiation trajectory-related gene signature to reveal the prognostic significance and immune landscape in prostate cancer based on multiomics analysis

Sun,

Tuo,

Chen

et al. 2024

Heliyon

View full text Add to dashboard Cite

“…GS catalyzes nitrate reduction of ammonia to glutamate during glutamine formation and MYC demethylates the GS promoter by TET3 upregulation, which upregulates thymine DNA glycosylase expression [ 165 ]. Such aberrant expression upregulates various cellular components, including glutamine and amino-acid transporters, to support tumor outgrowth, as observed in a human PCa model [ 165 , 166 ]. As both GS and GLS1 are transiently expressed in different tumor cell subcellular compartments, MYC can activate both reactions simultaneously in an individual cell; glutaminolysis occurs in mitochondria, whereas glutamine synthesis primarily takes place in the cytosol [ 167 ].…”

Section: Functional Roles Of Myc In Cancer Cellsmentioning

confidence: 99%

MYC Oncogene: A Druggable Target for Treating Cancers with Natural Products

Chan,

Zhang,

et al. 2024

Aging and disease

Self Cite

View full text Add to dashboard Cite

Various diseases, including cancers, age-associated disorders, and acute liver failure, have been linked to the oncogene, MYC . Animal testing and clinical trials have shown that sustained tumor volume reduction can be achieved when MYC is inactivated, and different combinations of therapeutic agents including MYC inhibitors are currently being developed. In this review, we first provide a summary of the multiple biological functions of the MYC oncoprotein in cancer treatment, highlighting that the equilibrium points of the MYC/MAX, MIZ1/MYC/MAX, and MAD (MNT)/MAX complexes have further potential in cancer treatment that could be used to restrain MYC oncogene expression and its functions in tumorigenesis. We also discuss the multifunctional capacity of MYC in various cellular cancer processes, including its influences on immune response, metabolism, cell cycle, apoptosis, autophagy, pyroptosis, metastasis, angiogenesis, multidrug resistance, and intestinal flora. Moreover, we summarize the MYC therapy patent landscape and emphasize the potential of MYC as a druggable target, using herbal medicine modulators. Finally, we describe pending challenges and future perspectives in biomedical research, involving the development of therapeutic approaches to modulate MYC or its targeted genes. Patients with cancers driven by MYC signaling may benefit from therapies targeting these pathways, which could delay cancerous growth and recover antitumor immune responses.

show abstract

Recent advances in bioaffinity strategies for preclinical and clinical drug discovery: Screening natural products, small molecules and antibodies

Jin,

Cui,

Fan

et al. 2024

Drug Discovery Today

View full text Add to dashboard Cite

Development of a dual targeting scaffold of SET7/MLL inhibitor for castration-resistant prostate cancer treatment

Cited by 4 publications

References 5 publications

Identification of cell differentiation trajectory-related gene signature to reveal the prognostic significance and immune landscape in prostate cancer based on multiomics analysis

Identification of cell differentiation trajectory-related gene signature to reveal the prognostic significance and immune landscape in prostate cancer based on multiomics analysis

MYC Oncogene: A Druggable Target for Treating Cancers with Natural Products

Recent advances in bioaffinity strategies for preclinical and clinical drug discovery: Screening natural products, small molecules and antibodies

Contact Info

Product

Resources

About